12 |
HUMAN INSULIN MARKET , BY REGION .................................................................................... 98 |
||
• 12.1 |
INTRODUCTION ............................................................................................................................................................... 99 |
||
• 12.2 |
NORTH AMERICA ........................................................................................................................................................... 100 |
||
• 12.2.1 |
U . S ............................................................................................................................................................... 103 |
||
• 12.2.2 |
CANADA ....................................................................................................................................................... 104 |
||
• 12.3 |
EUROPE .......................................................................................................................................................................... 106 |
||
• 12.3.1 |
GERMANY .................................................................................................................................................... 109 |
||
• 12.3.2 |
FRANCE ....................................................................................................................................................... 110 |
||
• 12.3.3 |
U . K ............................................................................................................................................................... 112 |
||
• 12.3.4 |
REST OF EUROPE ( ROE ).............................................................................................................................. 113 |
||
• 12.4 |
ASIA-PACIFIC ( APAC ).................................................................................................................................................... 115 |
||
• 12.4.1 |
JAPAN .......................................................................................................................................................... 118 |
||
• 12.4.2 |
CHINA .......................................................................................................................................................... 119 |
||
• 12.4.3 |
INDIA ............................................................................................................................................................ 120 |
||
• 12.4.4 |
REST OF ASIA-PACIFIC ( ROAPAC ).............................................................................................................. 122 |
||
• 12.5 |
REST OF THE WORLD ( ROW )......................................................................................................................................... 124 |
||
13 |
COMPETITIVE LANDSCAPE ..................................................................................................... 126 |
||
• 13.1 |
OVERVIEW ...................................................................................................................................................................... 126 |
||
• 13.2 |
MARKET SHARE ANALYSIS ........................................................................................................................................... 127 |
||
• 13.2.1 |
HUMAN INSULIN DRUGS MARKET ............................................................................................................. 129 |
||
• 13.2.2 |
HUMAN INSULIN DELIVERY DEVICES MARKET ......................................................................................... 130 |
||
• 13.3 |
COMPETITIVE SCENARIO .............................................................................................................................................. 131 |
||
• 13.4 |
RECENT DEVELOPMENTS ............................................................................................................................................. 132 |
||
• 13.4.1 |
GEOGRAPHICAL EXPANSIONS .................................................................................................................... 132 |
||
• 13.4.2 |
AGREEMENTS , COLLABORATIONS , AND PARTNERSHIPS ......................................................................... 133 |
||
• 13.4.3 |
NEW PRODUCT LAUNCHES ........................................................................................................................ 134 |
||
• 13.4.4 |
AWARENESS PROGRAMS ............................................................................................................................ 136 |
||
• 13.4.5 |
FUNDING & SCHOLARSHIPS ...................................................................................................................... 137 |
||
• 13.4.6 |
STRATEGIC ACQUISITIONS ......................................................................................................................... 138 |
||
• |